Literature DB >> 26292188

Blockade of GPR55 in the dorsolateral striatum impairs performance of rats in a T-maze paradigm.

Bruno A Marichal-Cancino1, Asai Sánchez-Fuentes, Mónica Méndez-Díaz, Alejandra E Ruiz-Contreras, Oscar Prospéro-García.   

Abstract

To investigate the role of GPR55 receptors, which are expressed in human and rat striatum (a structure that regulates procedural memory), Wistar rats received five training sessions (10 trials/session, 1 session/day) to solve a T-maze paradigm. From these data, we constructed learning curves following pharmacological manipulation of GPR55. Five minutes before each session, animals received bilateral intradorsolateral striatum injections of noladin-ether (3.1 nmol/l; endogenous agonist of GPR55 and CB1 receptors), CID16020036 (5.6 nmol/l; GPR55 antagonist), AM251 (5.6 nmol/l; CB1 antagonist), or a combination of noladin-ether with each antagonist. Noladin-ether by itself induced no significant changes in the learning curve. Nevertheless, while simultaneously blocking CB1 receptors (with AM251), noladin-ether improved acquisition. In contrast, while simultaneously blocking GPR55 (with CID16020036), noladin-ether weakened acquisition. CID16020036 by itself impaired learning, whereas AM251 by itself reduced the efficiency in the task. There were no differences between groups in the latency to reach the arms from the starting point; thus, no motor coordination impairments interfered with this task. These results strongly suggest a role of GPR55 in procedural memory and constitute the first evidence indicating that this receptor regulates cognitive processes.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26292188     DOI: 10.1097/FBP.0000000000000185

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  7 in total

1.  A putative lysophosphatidylinositol receptor GPR55 modulates hippocampal synaptic plasticity.

Authors:  Katrina Hurst; Corinne Badgley; Tanner Ellsworth; Spencer Bell; Lindsey Friend; Brad Prince; Jacob Welch; Zack Cowan; Ryan Williamson; Chris Lyon; Brandon Anderson; Brian Poole; Michael Christensen; Michael McNeil; Jarrod Call; Jeffrey G Edwards
Journal:  Hippocampus       Date:  2017-06-27       Impact factor: 3.899

Review 2.  The Periaqueductal Gray and Its Extended Participation in Drug Addiction Phenomena.

Authors:  Priscila Vázquez-León; Abraham Miranda-Páez; Jesús Chávez-Reyes; Gonzalo Allende; Paulino Barragán-Iglesias; Bruno A Marichal-Cancino
Journal:  Neurosci Bull       Date:  2021-07-24       Impact factor: 5.271

Review 3.  Advances in the Physiology of GPR55 in the Central Nervous System.

Authors:  Bruno A Marichal-Cancino; Alfonso Fajardo-Valdez; Alejandra E Ruiz-Contreras; Monica Mendez-Díaz; Oscar Prospero-García
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 4.  Advances in Neurobiology and Pharmacology of GPR12.

Authors:  Gonzalo Allende; Jesús Chávez-Reyes; Raquel Guerrero-Alba; Priscila Vázquez-León; Bruno A Marichal-Cancino
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

5.  Intrapallidal injection of cannabidiol or a selective GPR55 antagonist decreases motor asymmetry and improves fine motor skills in hemiparkinsonian rats.

Authors:  Felipe Patricio; Eliud Morales Dávila; Aleidy Patricio-Martínez; Nayeli Arana Del Carmen; Isabel Martínez; José Aguilera; Jose Manuel Perez-Aguilar; Ilhuicamina Daniel Limón
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

Review 6.  Cannabinoid Modulation of Dopamine Release During Motivation, Periodic Reinforcement, Exploratory Behavior, Habit Formation, and Attention.

Authors:  Erik B Oleson; Lindsey R Hamilton; Devan M Gomez
Journal:  Front Synaptic Neurosci       Date:  2021-06-10

7.  CB1 Activity Drives the Selection of Navigational Strategies: A Behavioral and c-Fos Immunoreactivity Study.

Authors:  Daniela Laricchiuta; Francesca Balsamo; Carlo Fabrizio; Anna Panuccio; Andrea Termine; Laura Petrosini
Journal:  Int J Mol Sci       Date:  2020-02-06       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.